Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is a leading fertility benefits platform with strong growth potential, supported by favorable demographics, partnerships, and a unique model. The company has shown strong clinical outcomes and retention, driving strong growth in the fully insured employer market. With a focus on adding 1 million new covered lives annually, efficient management and strong financials make Progyny a promising investment opportunity for the long-term.

Bears say

Progyny is a benefits management company that specializes in fertility, family building, and women's health benefits solutions. While the company has maintained a strong client retention rate and has won a significant share of competitive decisions, its market share gains may not be sustainable in the long term as the market matures and more competitors enter. Additionally, Progyny's expansion into the insurance market introduces a different risk profile and may impact profitability. It remains to be seen if the pharmacy benefit management platform and other modernization initiatives will result in increased profitability for the company.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.